The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma

Cancer Research

Volumn 56, Issue 9, 1996, Pages 2178-2184

  Herod, J Jonathan O ^a   Eliopoulos, Aristides G ^a   Warwick, Jane ^a   Niedobitek, Gerald ^a   Young, Lawrence S ^a   Kerr, David J ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER SURVIVAL; DNA SEQUENCE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; OVARY CARCINOMA; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS;

DRUG RESISTANCE, NEOPLASM; FEMALE; GENE TRANSFER TECHNIQUES; HUMANS; OVARIAN NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029874185     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Dive, C , and Hickman, J. A Drug-target interactions: only the first step in the commitment to programmed cell death Br J. Cancer, 64: 192-196, 1991.
2. Dive, C., and Wyllie, A H. Apoptosis and cancer chemotherapy. In: J A. Hickman and T. R. Tritton (eds.), Cancer Chemotherapy, pp 21-56 Oxford, United Kingdom: Blackwell Scientific Publications, Ltd , 1993.
3. Tsujimoto, Y., Gorham, J. S. C., Jaffe, E., and Croce, C M. The t(14:18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining. Science (Washington DC), 299: 1390-1393, 1985.
4. Cleary, M. L , Smith, S D., and Sklar, J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell, 47. 19-28, 1986
5. Hockenbery, D., Nunez, G., Milliman, C. Schreiber, R. D., and Korsmeyer, S. J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature (Lond.), 348. 334-336, 1990.
6. Klefstrom, J , Vastrik, I., Saksela, E., Valle, J , Eilers, M., and Alitalo, K c-Myc induces cellular susceptibility to the cytotoxic action of TNF-α. EMBO J., 13: 5442-5450, 1994.
7. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth & Differ., 4: 41-47, 1993.
8. Pezzella, F., Turley, H. Kuzu, I., Tungekar, M. F., Dunnill, M S., Pierce, C. B , Harris, A., Gatter, K. C., and Mason, D. M. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med, 329. 690-694, 1993.
9. Hockenben., D M., Zutter, M., Hickey, W., Nahm, M., and Korsmeyer, S J bcl-2 protein is topographically restricted to tissues characterized by apoptotic cell death. Proc Natl. Acad. Sci. USA, 88: 6961-6965, 1991
10. Leek, R. D., Kaklamanis, L., Pezzella, F., Gatter, K. C., and Harris, A L bcl-2 in normal human breast and carcinoma, association with oestrogen receptor-positive, epidermal growth factor receptor-negative tumours and in situ cancer. Br. J. Cancer, 69: 135-139, 1994.
11. Reed, J. C., Cuddy, M., Slabiak, T , Croce, C. M., and Nowell, P. C. Oncogenic potential of bcl-2 demonstrated by gene transfer. Nature (Lond.), 336: 259-261, 1988.
12. McDonnell, T. J , Deane, N., and Platt, F. M. Deregulated bcl-2 immunoglobulin transgenic mice demonstrate extended B-cell survival and follicular lymphoproliferation. Cell, 57. 80-88, 1989.
13. Myashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1992.
14. McDonnell, T. J., Troncoso, P., Brisbay, S. M., Logothetis, C., Leland, W. K , Cheung, J-T. H , Tu, S-M., and Campbell, M. L. Expression of the proto-oncogene bcl-2 in the prostate and its association with the emergence of androgen-independent prostate cancer. Cancer Res., 52: 6940-6944, 1992.
15. Hague, A., Moorghen, M., Hicks, D., Chapman, M., and Paraskeva, C. Bcl-2 expression in human colorectal adenomas and carcinomas. Oncogene, 9: 3367-3370, 1994.
16. Haldar, S., Negrini, M., Monne, M., Sabbioni, S , and Croce, C. M. Down-regulation of bcl-2 by p53 in breast cancer cells Cancer Res , 54: 2095-2097, 1994.
17. Silvestrini, R., Veneroni, S , Daidone, M. G., Benini, E., Boracchi, P., Mezzetti, M., Di Fronzo, G., Rilke, F , and Veronesi, U. The Bcl-2 protein, a prognostic indicator strongly related to p53 protein in lymph node-negative breast cancer patients. J. Natl Cancer Inst., 86: 499-504, 1994.
18. Brown, R. p53. a target for new anti-cancer drugs or a target for old drugs? Ann Oncol , 4: 623-629, 1993.
19. Bartek, J., Bartkova, J , and Vojtesek, B. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of malignancies. Oncogene, 6: 1699-1703, 1991.
20. Harris, A. L. Mutant p53 - the commonest genetic abnormality in human cancer? J. Pathol. 162: 5-6, 1990.
21. Diller, L., Kassel, J., Nelson, C E., Gryka, M. A., Litwak, G., Gebhardt, M., Bressac, B., Ozturk, M , Baker, S. J , Vogelstein, B., and Friend, S. H. p53 functions as a cell cycle control protein in osteosarcomas. Mol. Cell Biol., 10: 5772-5781, 1990.
22. Yonish-Rouach, E , Resnitzky, D., Lotem, J., Sachs, L., Kimchi, A., and Oren, M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin 6. Nature (Lond.), 352: 345-347, 1991.
23. Chang, E. H., Pirollo, K F., Zou, Z. Q., Cheung, H. Y., Lawler, E. L., Garner, R., White, E., Bernstein, W. B., Fraumeni, J F., and Blattner, W. A. Oncogenes in radioresistant non-cancerous skin fibroblasts from a cancer-prone family. Science (Washington DC), 237: 1036-1039, 1987.
24. Behrens, B. C., Hamilton, T. C., Masuda, H , Grotzinger, K. R., Whang-Peng, J , Louie, K G , Knutsen, T., McKoy, W. M., Young, R. C., and Ozols, R. F. Characterization of a cis-platinum resistant ovarian cell line and its use in evaluation of platinum analogues Cancer Res , 47: 414-418, 1987.
25. Tsujimoto, Y Over-expression of the human bcl-2 gene product results in growth enhancement of Epstein-Barr virus-immortalized B-cells. Proc. Natl Acad Sci. USA, 86: 1958-1962, 1989.
26. Dawson, C. W., Rickinson, A. B., and Young, L. S. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature (Lond.), 344: 777-780, 1990.
27. Mosmann, T. Rapid colorimetric assay for cellular growth and survival. J. Immunol. Methods, 65: 55-63, 1983.
28. Luesley, D M., Blackledge, G , Kelly, K., Wade-Evans, T., Fielding, J., Lawton, F , Hilton, C , Rollason, T. P , Jordan, J A., and Latief, T Failure of second-look laparotomy to influence survival in epithelial ovarian cancer. Lancet, 2. 599-603, 1988.
29. Redman, C. W. E , Warwick, J., Luesley, D. M , Varma, R., Lawton, F. G., and Blackledge, G R. P. Intervention debulking surgery in advanced epithelial ovarian cancer. Br. J. Obstet. Gynaecol. 101. 142-146, 1994
30. Banks, L., Matlashewski, G., and Crawford, L. V. Isolation of human p53 specific monoclonal antibodies and their use in the study of human p53 expression. Eur J. Biochem , 159: 529-534, 1986.
31. Kalbfleisch, J. D , and Prentice, R. L. The Statistical Analysis of Failure Time Data. New York: John Wiley & Sons., Inc., 1980.
32. Miller, R. G. J. Simultaneous Statistical Inference New York: Springer-Verlag, 1981
33. Marks, J R., Davidoff, A M., Kerns, B J., Humphrey, P A , Pence, J. C., Dodge, R. K , Clarke, P. D., Iglehart, J. D , Bast, R. J , and Berchuck. A. Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res., 51: 2979-2984, 1991.
34. Kohler, M. F., Kerns, B. J , Humphrey, P A , Marks, J R , Bast, R. J , and Berchuck, A. Mutation and overexpression of p53 in early-stage epithelial ovarian carcinoma Obstet. Gynecol., 81. 643-650, 1993.
35. Kiyokawa, T. Alteration of p53 in ovarian cancer: its occurrence and maintenance in tumour progression hit. J. Gynecol Pathol., 13. 311-318, 1994.
36. Maestro, R., Dolcetti R., Gasparotto, D., Doglioni, C , Pelucchi, S , Barzan, L , Grandi, E , and Boiocchi, M. High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx Oncogene, 7: 1159-1166, 1992
37. Momand, J., Zambetti, G. P , Olsen, D C , George, D , and Levine, A J. The indin-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation Cell, 69. 1237-1245, 1992.
38. Wynford-Thomas, D p53 in tumour pathology: can we trust immumocytochemistry? J. Pathol., 166: 329-330, 1992
39. Pietenpol, J. A , Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K W , and Vogelstein, B Paradoxical inhibition of solid tumor cell growth by bcl-2. Cancer Res., 54: 3714-3717, 1994.
40. Oltvai, Z N., and Korsmeyer, S. J. Checkpoints of duelling dimers foil death wishes. Cell, 79 189-192, 1994
41. Krajewski, S , Krajewska, M., Shabaik, A , Wang, H-G., Irie, S., Fong, L., and Reed, J C. Immunohistochemical analysis of in vivo patterns of bcl-x expression. Cancer Res., 54 5501-5507, 1994.